Doseology Enters Energy Market with Nicotine-Free Caffeine Pouches

KELOWNA, BC – January 21, 2026 – Biotechnology firm Doseology Sciences Inc. is stepping into the burgeoning energy products arena with a new format aimed at disrupting the status quo: non-nicotine, caffeine-based oral pouches. The company announced today it has begun a pilot production run under its recently acquired Feed That Brain® brand, positioning the product as a controlled, discreet alternative to traditional energy drinks.

This move signals a strategic shift for Doseology, betting that modern consumers are seeking more measured and predictable ways to manage their energy levels, away from the high-sugar, high-volume beverages that dominate the market. The new pouches, which contain no nicotine, are designed to deliver caffeine in a pre-portioned, non-liquid format, emphasizing user control and consistency over sheer intensity.

Rethinking the Energy Boost

The global market for energy-focused products is massive and growing. Valued at nearly $80 billion in 2024, the energy drink segment alone is projected to soar past $125 billion by 2030, according to data from Grand View Research. However, this growth has been shadowed by increasing consumer and regulatory scrutiny over high sugar content, large portion sizes, and the health effects of excessive consumption.

Doseology aims to carve out a niche within this landscape by addressing these concerns directly. Unlike energy drinks or shots, the pouch format offers a sugar-free, zero-carbonation delivery system that is both portable and discreet. By placing a small pouch between the gum and cheek, users can absorb caffeine through the oral mucosa, allowing for a different kind of user experience.

"This pilot reflects a disciplined and intentional approach to evaluating new product formats within our platform," said Tim Corkum, President & COO of Doseology, in a statement. The company's strategy focuses on what it calls "next-generation stimulation," prioritizing measured and predictable effects. This pilot is the first major step in testing that vision in the real world. "Feed That Brain brings a strong foundation in functional product design, and this initiative allows us to assess caffeine-based, pouch-format energy delivery under a measured and compliant framework," Corkum added.

A Strategic Bet on 'Feed That Brain'

The choice of the Feed That Brain® brand is a calculated one. Doseology acquired the brand from Joseph Mimran & Associates Inc. in August 2025 for approximately $400,000 in company stock. Prior to the acquisition, Feed That Brain was known for its functional gummies and nootropic formulations designed to support cognitive performance and wellness.

By repurposing this established wellness brand, Doseology is attempting to position its new pouches not as a mere tobacco alternative, but as a sophisticated tool for performance-minded individuals. This strategic framing aims to appeal to a demographic that values intention and thoughtful product design. Joseph Mimran, a renowned Canadian brand architect and co-founder of Feed That Brain, has joined Doseology as a Strategic Advisor, a move that lends significant credibility to the company's brand-building ambitions.

"Feed That Brain was created to support focus and performance in everyday life," stated Mimran, who is now an equity holder in Doseology. "I'm encouraged by Doseology's disciplined approach to product development, regulatory compliance, and brand building as this next chapter unfolds."

For Doseology (CSE: MOOD), this pilot represents a significant strategic wager. While the company maintains a low-debt balance sheet, analyst reports have pointed to weak financial performance, including volatile revenue and continued losses. Success in the oral stimulant category could provide a much-needed growth engine, but the path is not without its challenges.

Navigating a Crowded and Controversial Field

Doseology is not the first to market with caffeine pouches. The emerging category already features a number of competitors, including brands like Grinds Coffee Pouches, TeaZa Energy, and Cyclone Pods, many of which also market themselves as nicotine-free, sugar-free alternatives to traditional energy or tobacco products. These brands have found success in niche markets, from gamers seeking enhanced focus to individuals looking for a substitute for chewing tobacco.

Beyond the competition, a more significant hurdle lies in the health and regulatory landscape. While the pouch format offers benefits like portion control, health experts express caution. Caffeine delivered through oral pouches is absorbed rapidly through the mucous membranes in the mouth, leading to a faster onset of effects. This can increase the risk of overstimulation, anxiety, and heart palpitations, especially if users consume multiple pouches in a short period.

In the United States, these products are typically regulated as dietary supplements, meaning they do not require pre-market approval from the Food and Drug Administration (FDA). While the FDA considers 400 milligrams of caffeine a day to be safe for most healthy adults, the discreet nature of pouches could lead to "mindless consumption" that pushes users well beyond that limit. Some pouches from competing brands can contain 50-100mg of caffeine or more, making it easy to consume the equivalent of several cups of coffee without realizing it.

Concerns are particularly high for vulnerable populations. Health professionals have voiced alarm over the potential appeal of flavored pouches to teenagers and young adults, whose developing nervous systems are more susceptible to the negative effects of high caffeine intake.

A Data-Driven Path Forward

Doseology appears to be aware of these challenges, emphasizing its "measured and compliant framework." The company has stressed that the current production run is an exploratory pilot, not a full commercial launch. The products will be introduced through a limited direct-to-consumer initiative in the coming weeks, with the primary goal of gathering real-world data and consumer feedback.

The insights gained from this pilot are intended to inform every aspect of the product's future, from formulation and delivery design to broader commercialization strategy. By starting small and focusing on data, Doseology hopes to refine its offering and build a scalable pathway for future products. This controlled approach will be critical as the company attempts to balance innovation with responsibility in the complex and rapidly evolving energy market. The success of this pilot will ultimately determine if Doseology's vision for a more controlled caffeine experience can resonate with consumers and navigate the intricate web of market competition and public health scrutiny.